See What HealthDay Can Do For You
Contact Us

Mouse Study Suggests Type 2 Diabetes Potential Treatment

EGFR tyrosine kinase inhibitor PD153035 improved glucose tolerance, insulin resistance

THURSDAY, Dec. 17 (HealthDay News) -- Researchers in Brazil have found that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor PD153035 improves insulin sensitivity and glucose tolerance in mice fed on a high-fat diet, and may offer a treatment approach for type 2 diabetes, according to a study in the December issue of Diabetes.

Patricia O. Prada, of the State University of Campinas in Brazil, and colleagues put mice on a high-fat diet for eight weeks, then administered PD153035 by tube to the mice for two weeks. They conducted glucose tolerance tests and insulin tolerance tests, as well as tests for biomarkers of inflammation.

The researchers found that treatment with PD153035 for a single day reduced the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, pointing to a reduction of the proinflammatory state in the adipose tissue macrophages. With two weeks of continued treatment, the mice exhibited a marked improvement in glucose tolerance, as well as improved insulin signaling and reduced insulin resistance.

"After 14 days of the drug administration, there was a marked improvement in glucose tolerance; a reduction in insulin resistance; a reduction in macrophage infiltration in adipocytes and in TNF-α, IL-6, and free fatty acids; accompanied by an improvement in insulin signaling in liver muscle and adipose tissue. We, therefore, suggest that PD153035 presents an attractive opportunity for the treatment of insulin resistance and type 2 diabetes," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing